RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome-Reference-Cited by-同舟云学术

RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome

Published:2023-07 Issue:5 Volume:24 Page:415-428
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Nishio Makoto^ORCID,Paz-Ares Luis,Reck Martin,Nakagawa Kazuhiko,Garon Edward B.,Popat Sanjay,Ceccarelli Matteo,Graham Hillary T.,Visseren-Grul Carla,Novello Silvia

Funder

Eli Lilly and Company

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference51 articles.

1. Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications;Zito Marino;Int J Med Sci,2019

2. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update;Bethune;J Thorac Dis,2010

3. Understanding EGFR heterogeneity in lung cancer;Passaro;ESMO Open,2020

4. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer;Leonetti;British J Cancer,2019

5. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study;Shi;Ann Oncol,2017

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of resistance and correlation between pre-treatment co-alterations and p-prognosis to osimertinib in chemo-naïve advanced non-small cell lung cancer;Lung Cancer;2024-09

2. Clinicopathological and molecular characterization of resected lung adenocarcinoma: Correlations with histopathological grading systems in Chinese patients;Pathology - Research and Practice;2024-07

3. Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer;The Lancet Regional Health - Europe;2024-03

4. Osimertinib in uncommon EGFR exon 21 L861R and EGFR exon 18 deletion-insertion mutant non-small cell lung cancer—case report;Translational Lung Cancer Research;2024-02

5. The heterogeneous impact of targeted therapy on the prognosis of stage III/IV colorectal cancer patients with different subtypes of TP53 mutations;Cancer Medicine;2023-12